Associations with the Health-Related Quality of Life measure 15D in psoriatic arthritis patients tested in univariate and multivariate linear regression models. Only variables with a p value <0.10 in the univariate analysis were tested in the multivariate analysis, which was adjusted for age, gender and BMI independent of their significance in the univariate analyses. Apart from age, gender and BMI, only variables with a p value <0.01 are displayed in the multivariate analysis
| Univariate analyses | Adjusted analyses | |||
|---|---|---|---|---|
| B (95% CI) | P value | B (95% CI) | P value† | |
| Age, years | −0.001 (−0.003, 0.000) | 0.15 | −0.001 (−0.002, 0.000) | 0.16 |
| Female gender | −0.046 (−0.079, −0.012) | 0.008 | 0.016 (−0.004, 0.035) | 0.118 |
| BMI, kg/m2 | −0.004 (−0.008, 0.000) | 0.057 | 0.001 (−0.001, 0.003) | 0.47 |
| Current smoking | −0.060 (−0.106, −0.014) | 0.011 | ||
| Part time/full time employed/working | 0.084 (0.052, −0.116) | <0.001 | 0.021 (0.000, 0.041) | 0.045 |
| PsA disease duration, years | −0.001 (−0.004, 0.001) | 0.36 | ||
| CRP, mg/L | 0.000 (−0.002, 0.002) | 0.71 | ||
| TJC68 | −0.003 (−0.005, −0.002) | <0.001* | ||
| SJC66 | −0.005 (−0.021, 0.012) | 0.58 | ||
| DAPSA, range 0-164 | −0.004 (−0.005, −0.003) | <0.001 | ||
| PASDAS | −0.097 (−0.131, −0.062) | <0.001‡ | ||
| MASES, range 0-13 | −0.013 (−0.018, −0.008) | <0.001 | ||
| IGA, VAS 0–100 mm | −0.002 (−0.004, −0.001) | <0.001 | ||
| PGA, VAS 0–100 mm | −0.003 (−0.003, −0.002) | <0.001* | ||
| Pain, VAS 0–100 mm | −0.003 (−0.003, −0.002) | <0.001 | ||
| Fatigue, VAS 0–100 mm | −0.002 (−0.003, −0.002) | <0.001 | −0.001 (−0.001, −0.000) | <0.001 |
| Morning stiffness, hour | −0.025 (−0.039, −0.012) | <0.001 | ||
| Sleep disturbance, NRS 0-10 | −0.024 (−0.028, −0.020) | <0.001 | −0.008 (−0.013, −0.004) | <0.001 |
| Anxiety/depression, range 1-3 | −0.094 (−0.119, −0.070) | <0.001 | −0.047 (−0.064, −0.030) | <0.001 |
| MHAQ, range 0-3 | −0.172 (−0.204, −0.141) | <0.001 | −0.053 (−0.086, −0.020) | 0.002 |
| Exercise ≥1 time per week | 0.029 (−0.005, 0.064) | 0.098 | ||
| Power Doppler signal present in any joints, entheses or tendons | −0.006 (−0.040, 0.029) | 0.74 | ||
| Power Doppler sum score in joints, entheses and tendons (range 0–347) | 0.003 (−0.006, 0.012) | 0.55 | ||
| Comorbidities ≥1 | −0.059 (−0.092, −0.025) | 0.001 | −0.031 (−0.050, −0.012) | 0.002 |
| PASI, range 0–72 | −0.002 (−0.007, 0.003) | 0.36 | ||
| PASI score ≥10 | −0.055 (−0.120, 0.009) | 0.091 | ||
| DLQI, range 0–30 | −0.007 (−0.012, −0.003) | 0.002 | ||
| Current use of bDMARD | −0.006 (−0.042, 0.030) | 0.75 | ||
| Current use of csDMARD | −0.005 (−0.040, 0.030) | 0.77 | ||
| Ever use of bDMARD | −0.013 (−0.049, 0.022) | 0.46 | ||
| Ever use of csDMARD | −0.039 (−0.095, 0.016) | 0.16 | ||
*Not in the final multivariate model.
†With DAPSA in the model.
‡The independent associations remained overall the same when DAPSA was replaced by PASDAS in the model.
bDMARDs, biologic disease-modifying antirheumatic drugs; BMI, body mass index; CRP, C reactive protein; csDMARDs, conventional synthetic DMARDs; DAPSA, Disease Activity Index for Psoriatic Arthritis; DLQI, Dermatology Life Quality Index; IGA, Investigator’s Global Assessment; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; MHAQ, Modified Health Assessment Questionnaire; NRS, Numeric Rating Scale; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area Severity Index; PGA, Patient’s Global Assessment; PsA, psoriatic arthritis; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analogue Scale.